Avandra Appoints Industry Veterans to Scale Healthcare Data Interoperability

The appointment of Mark J. Woodka and Jack Noonan to Avandra’s leadership team marks a significant inflection point for the healthcare technology firm as it seeks to capitalize on the growing demand for data liquidity. As the industry moves past basic electronic health record (EHR) adoption toward a more sophisticated era of data utility, Avandra is positioning itself to solve the persistent 'last mile' of data integration. This challenge—ensuring that disparate data sets from payers, providers, and labs are not just exchanged but are actionable and normalized—remains one of the most difficult bottlenecks in Health IT. By bringing in a seasoned Chief Revenue Officer and a high-profile board member, Avandra is signaling to the market that its technology is ready for enterprise-scale deployment across the national healthcare ecosystem.

Mark J. Woodka’s transition to Chief Revenue Officer is particularly noteworthy given his 14-year tenure as CEO of OnShift. During his time there, Woodka transformed a niche software provider into a dominant force in the post-acute and senior care markets. His experience is critical for Avandra because the post-acute sector has historically been a significant gap in healthcare data exchange. Woodka’s deep understanding of how to sell complex, high-value technology into fragmented and traditionally tech-resistant markets will be essential as Avandra seeks to expand its footprint among both payers and large health systems. His background at Trizetto further reinforces his expertise in the payer-provider interface, a core focus of Avandra’s value proposition for risk adjustment and quality reporting.

“

As the former CEO of SPSS, he led the company through its $1.2 billion acquisition by IBM, a landmark deal in the data analytics space.

Complementing Woodka’s operational focus is the addition of Jack Noonan to the Board of Directors. Noonan’s pedigree is rooted in high-growth enterprise technology and successful exits. As the former CEO of SPSS, he led the company through its $1.2 billion acquisition by IBM, a landmark deal in the data analytics space. His presence on the board suggests that Avandra is not just looking for incremental growth but is likely preparing for a major capital event, such as a significant Series C funding round or a strategic exit. Noonan’s experience on the boards of public companies like Morningstar and Fleetmatics brings a level of governance and strategic oversight that is often a prerequisite for institutional investors looking at the next generation of Health IT leaders.

From a market perspective, Avandra is operating in an increasingly crowded field that includes well-funded competitors like Redox and Health Gorilla, as well as the interoperability arms of giants like Oracle Health and Epic. However, the 'last mile' focus—specifically the normalization and enrichment of data for clinical and financial use cases—is where the highest margins currently reside. As the Centers for Medicare & Medicaid Services (CMS) continues to push for greater transparency and data access through mandates like the Interoperability and Patient Access final rule, the demand for Avandra’s services is expected to surge. The company’s ability to translate raw data into the 'gold standard' records required for risk adjustment and care coordination will be the primary driver of its valuation.

Looking ahead, the industry should watch for Avandra to leverage this new leadership to secure larger, multi-year contracts with national payers and integrated delivery networks (IDNs). The combination of Woodka’s sales leadership and Noonan’s strategic guidance suggests a shift from a product-led growth model to a more aggressive, sales-driven enterprise strategy. If Avandra can successfully integrate these veterans into its culture, it may well become the primary bridge between the legacy data silos of the past and the AI-driven healthcare ecosystem of the future, where high-quality data is the essential currency for survival.